Table 4.
Selected trials in the treatment of NSCLC
| |
Author |
n |
Stages |
Selection of study population |
Treatment |
Esoph. toxicity ≥gr.3 (%) |
Tumor control rate at 2 y.: Local/locoreg. |
Overall survival |
|
|---|---|---|---|---|---|---|---|---|---|
| Median (mo) | 2/5 y (%) | ||||||||
| A |
Curran et al. [1] |
195 |
II, III |
good PS |
2 × Ch, sequ 60 Gy |
4 |
NR |
14.6 |
-/10 |
| |
|
195 |
II, III |
good PS |
2 × Ch, sim 60 Gy |
23 |
NR |
17 (p = 0.046) |
-/16 |
| |
|
187 |
II, III |
good PS |
2 × Ch, sim 69.6 Gy/1.2 Gy bid |
45 |
NR |
16 |
-/13 |
| |
Furuse et al. [20] |
158 |
III |
--- |
2 × Ch, sequ 56 Gy |
2 |
NR |
13.3 |
27/9 |
| |
|
156 |
III |
--- |
2 × Ch, sim 56 Gy split course |
3 |
NR |
16.5 (p = 0.04) |
35/16 |
| |
Fournel et al. [21] |
101 |
III |
good PS |
3 × Ch, sequ 66 Gy |
3 |
NR |
14.5 |
26/14(4y) |
| |
|
100 |
III |
good PS |
2 × Ch, sim 66 Gy, plus 2 × Ch. |
32 |
NR |
16.3 (p = 0,24) |
39/21(4y) |
| B |
Stinchcombe et al. [25] |
62 |
III |
good PS, V20 < 35% |
Ind Ch 2×, 60–74 Gy sim Ch |
8 |
NR |
25 |
-/27 |
| |
Bradley et al. [26] |
53 |
I–III |
good PS, V20 < 30% |
74 Gy, sim Ch weekly |
12 |
NR |
25.9 |
NR |
| C |
Kong et al. [3] |
106 |
I–III |
unselected, long accrual period |
63–102.9 Gy/2.1 Gy/6–10w.; 19% ind Ch 2× |
7 |
-/40 |
19.0 |
37/13 |
| |
Bradley et al. [6] |
177 |
I–III |
44% stage I, V20 <37% |
70.9–90.3 Gy/2.15 Gy/6.5–8,5 w.; 14% ind Ch |
3 |
--- |
NR |
NR |
| |
Wurstbauer et al. [12] |
124 |
I–III |
unselected |
80–96 Gy primary t., 69.3 Gy nodes/2.0–2.2 Gy/8–9 w., 47% ind Ch |
0 |
-/49 |
19.6 |
39/11 |
| D |
Van Baardwijk et al. [7] |
166 |
I–III |
unselected |
64.8 Gy (50.5–79.2)/1.8 Gy bid, i = 8 h/4.5 w.; 55% ind. Ch 3× |
5 |
NR |
21.0 |
45/-- |
| |
Saunders et al. [31] |
225 |
I–III |
good PS |
60 Gy/2 Gy/6 weeks |
3 |
NR |
13 |
21/NR |
| |
|
338 |
I–III |
good PS |
54 Gy/1.5 Gy tid/12d/i ≥ 6 h |
19 |
NR |
16.5 (p = 0.008) |
30/NR |
| |
Wurstbauer et al. [13] |
30 |
I–III |
unselected |
84.6 Gy primary t., 63 Gy nodes/1.8 Gy bid, i >10 h/5 w.; 63% ind. Ch 2× |
7 |
--/61 |
27.7 |
63/23 |
| |
Current study |
160 |
I–III |
unselected |
73.8–90.0 Gy primary t., 59.4 Gy nodes/1.8 Gy bid, i >10 h/5 w.; 66% ind. Ch 2× |
4 |
77/70 |
28.0 |
57/19 |
| (116 | III A + B | 24.3 | 51/18) | ||||||
A. Randomized studies comparing sequential versus simultaneous radio-/chemotherapy. B. Further simultaneous studies. C. Radiation dose escalation trials. D. Trials employing accelerated radiotherapy.
Abbreviations: NR = not reported; Ch = chemotherapy; sequ = sequential, sim = simultaneous, ind = induction, PS = Performance status.